

Dylan C Dean

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8557457/publications.pdf>

Version: 2024-02-01

20
papers

853
citations

759055

12
h-index

752573

20
g-index

22
all docs

22
docs citations

22
times ranked

1278
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Exosomes promote pre-metastatic niche formation in ovarian cancer. <i>Molecular Cancer</i> , 2019, 18, 124. | 7.9 | 190 |
| 2 | Advances in immune checkpoint inhibitors for bone sarcoma therapy. <i>Journal of Bone Oncology</i> , 2019, 15, 100221. | 1.0 | 122 |
| 3 | RNA sequencing (RNA-Seq) and its application in ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 152, 194-201. | 0.6 | 94 |
| 4 | The role of extracellular matrix in osteosarcoma progression and metastasis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 178. | 3.5 | 76 |
| 5 | Emerging next-generation sequencing-based discoveries for targeted osteosarcoma therapy. <i>Cancer Letters</i> , 2020, 474, 158-167. | 3.2 | 54 |
| 6 | Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in ovarian cancer. <i>FASEB Journal</i> , 2019, 33, 5990-6000. | 0.2 | 47 |
| 7 | From genomics to metabolomics: emerging metastatic biomarkers in osteosarcoma. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 719-731. | 2.7 | 46 |
| 8 | Chimeric antigen receptor T (CAR-T) cell immunotherapy for sarcomas: From mechanisms to potential clinical applications. <i>Cancer Treatment Reviews</i> , 2020, 82, 101934. | 3.4 | 45 |
| 9 | Cancer testis antigens in sarcoma: Expression, function and immunotherapeutic application. <i>Cancer Letters</i> , 2020, 479, 54-60. | 3.2 | 26 |
| 10 | ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592098285. | 1.4 | 17 |
| 11 | Cyclin E1 is a prognostic biomarker and potential therapeutic target in osteosarcoma. <i>Journal of Orthopaedic Research</i> , 2020, 38, 1952-1964. | 1.2 | 16 |
| 12 | Inhibition of ATR-Chk1 signaling blocks DNA double-strand-break repair and induces cytoplasmic vacuolization in metastatic osteosarcoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095690. | 1.4 | 14 |
| 13 | TAK cell-originated protein kinase (TOPK) is a Novel Prognostic and Therapeutic Target in Chordoma. <i>Cell Proliferation</i> , 2020, 53, e12901. | 2.4 | 11 |
| 14 | Expression and clinical implications of leucine-rich repeat containing 15 (LRRC15) in osteosarcoma. <i>Journal of Orthopaedic Research</i> , 2020, 38, 2362-2372. | 1.2 | 11 |
| 15 | Establishment and Characterization of a Recurrent Osteosarcoma Cell Line: OSA 1777. <i>Journal of Orthopaedic Research</i> , 2020, 38, 902-910. | 1.2 | 10 |
| 16 | Cyclin-dependent kinase 12 (CDK12) in chordoma: prognostic and therapeutic value. <i>European Spine Journal</i> , 2020, 29, 3214-3228. | 1.0 | 7 |
| 17 | TAK cell-originated protein kinase (TOPK): an emerging prognostic biomarker and therapeutic target in osteosarcoma. <i>Molecular Oncology</i> , 2021, 15, 3721-3737. | 2.1 | 5 |
| 18 | Prognostic Significance of Cyclin E1 Expression in Patients With Chordoma: A Clinicopathological and Immunohistochemical Study. <i>Frontiers in Oncology</i> , 2020, 10, 596330. | 1.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Expression and Clinical Significance of High-Mobility Group (HMGA2) Tj ETQg1 1 0.784314 rgB | 0.7 | 1 |
| 20 | Advances in the Molecular Biology of Chondrosarcoma. , 2021, , 27-52. | | 0 |